RET mutation and expression in small-cell lung cancer

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Small-cell lung cancer (SCLC) genomic characterization is hindered by limited surgical tumor access.
• Defining somatic mutations in SCLC is crucial for developing targeted therapies.
• This study aimed to assess biopsy specimen availability for genomic analysis in SCLC.

Purpose of the Study:

• To determine the feasibility of genomic studies using available SCLC biopsy specimens.
• To identify oncogenic drivers for initial analysis in SCLC.
• To investigate the role of RET signaling in SCLC.

Main Methods:

• DNA extraction from six SCLC tumor specimens (three primary, three metastatic).
• Genomic analysis using SEQUENOM platform technology.
• Functional studies in SCLC cell lines (H1048, SW1271) with wild-type and mutant RET overexpression.

Main Results:

• Limited availability (<3%) of primary-resected tumor tissue for comprehensive genomic analysis.
• Identification of an activating M918T RET somatic mutation in a metastatic SCLC specimen.
• Overexpression of mutant RET activated ERK signaling, MYC expression, and cell proliferation, sensitizing cells to RET inhibitors (vandetanib, ponatinib).
• SCLC cells showed significantly higher RET expression compared to lung adenocarcinoma cells.

Conclusions:

• A subset of SCLC patients may benefit from RET-targeting tyrosine kinase inhibitors.
• RET appears to play an emerging role in SCLC, similar to its role in non-small-cell lung cancer (NSCLC).
• Further investigation into RET alterations in SCLC is warranted.